Skip to main content
. 2023 Dec 7;12(4):429–439. doi: 10.1002/ueg2.12503

FIGURE 1.

FIGURE 1

Overall survival and Progression‐free survival in patients treated with atezolizumab/bevacizumab as a first‐line systemic treatment. (a) Overall survival was represented using Kaplan‐Meier curve with the number at risk under the X axis. Median overall survival was 13 months. (b) Progression‐free survival was represented using Kaplan‐Meier curve with the number at risk under the X axis. The median progression‐free survival was 3 months.